Charles River Laboratories Inter (NYSE: CRL) has reported earnings for its second fiscal quarter (ending June 30) of $1.75 versus $1.89 for the same period a year ago — a decline of -7%. Relative to the consensus estimate of $2.39, this was a shortfall of $-0.64. For the latest four quarters through June 30, E.P.S. were $8.41 versus $9.49 for the same period a year ago — a decline of -11%.
Recent Price Action
Charles River Laboratories Inter (NYSE: CRL) stock closed at $199.96 on 8/7/24 after a major decline of -12.6%. Moreover, trading volume in this decline was exceptionally high at 658% of normal. The stock has performed in line with the market over the last nine months and has declined -18.5% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be above the cost of capital, CRL is expected to continue to be an important Value Builder.
Charles River Laboratories Inter has a current Value Trend Rating of C (Neutral). This rating combines highly consistent signals from two proprietary PTR measures of a stock’s attractiveness. Charles River Laboratories Inter has a neutral Appreciation Score of 51 and a neutral Power Rating of 50, triggering the Neutral Value Trend Rating.
Rating Review
In light of this new information and highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment